AMENDMENTS TO THE CLAIMS:

Subject to an approval by the Examiner, please amend sole independent claim 1 and dependent claims 5, 11, 12, 14, 15 and cancel dependent claim 18, as follows:

1. **(Currently Amended)** A method of treating acute and chronic myeloid leukemia (AML & CML) and lymphoid leukemia, in a mammal, in order to obtain a percentage growth inhibition of at least one of promonocyte cells, Erythroleukemia cells, or CML's leukemic cells, said method comprising administering a pharmaceutical composition ~~comprising~~ that is a synergistic combination consisting essentially of a pharmaceutically effective amount of chlorogenic acid (CA) and 3-o-p-Coumaryl quinic acid (PCQ) isolated from any plant parts of *Piper betel* or any other source, ~~either individually or in a combination and~~ optionally along with pharmaceutically acceptable additives.

2. **(Original)** A method as claimed in claim 1, wherein, CA and PCQ both are isolated from any plant parts of *Piper betel* or are synthetically prepared.

3. **(Previously Presented)** A method as claimed in claim 1, wherein the selected mammal is a human being.

4. **(Original)** A method as claimed in claim 1, wherein, the additive is selected from a group consisting of nutrients such as proteins, carbohydrates, sugars, talc, magnesium stearate,

cellulose, calcium carbonate, starch-gelatin paste and/or pharmaceutically acceptable carriers, excipient, diluents or solvents.

5. **(Currently Amended)** A method as claimed in claim 1, wherein ratio of CA and PCQ present in the composition ranging from ~~1:0~~ 1:1 to 1:10~~, preferably 1:1~~.

6. **(Previously Presented)** A method as claimed in claim 1, wherein the said composition is administered to the mammal through oral, intravenous, intramuscular or subcutaneous routes.

7. **(Previously Presented)** A method as claimed in claim 1, wherein said composition is administered to the mammal at dose levels between 1 to 50 mg per kg body weight at least once in a day.

8. **(Original)** A method as claimed in claim 1, wherein the percentage growth inhibition of Erythroleukemia cells is about 30% with CA.

9. **(Original)** A method as claimed in claim 1, wherein the percentage growth inhibition of Erythroleukemia cells is about 8% with PCQ.

10. **(Previously Presented)** A method as claimed in claim 1, wherein the percentage growth inhibition of Erythroleukemia cells is about 50% with CA and PCQ used in combination.

11. **(Currently Amended)** A method as claimed in claim 1 ~~wherein~~, wherein the percentage growth inhibition of promonocyte cells is about 25% with CA.

12. **(Currently Amended)** A method as claimed in claim 1 ~~wherein~~, wherein the percentage growth inhibition of promonocyte cells is about 5% with PCQ.

13. **(Previously Presented)** A method as claimed in claim 1, wherein the percentage growth inhibition of promonocyte cells is about 55% with CA and PCQ used in combination.

14. **(Currently Amended)** A method as claimed in claim 1 ~~wherein~~, wherein the percentage growth inhibition of CML's leukemic cells is about 5% with CA.

15. **(Currently Amended)** A method as claimed in claim 1 ~~wherein~~, wherein the percentage growth inhibition of CML's leukemic cells is about 5% with PCQ.

16. **(Previously Presented)** A method as claimed in claim 1, wherein the percentage growth inhibition of CML's leukemic cells is about 25% with CA and PCQ used in combination.

17. **(Previously Presented)** A method as claimed in claim 1, wherein the percentage growth inhibition of leukemic cells is increased by increasing the concentration and time duration of exposure to CA and PCQ.

18. **(Cancelled)**